Potential novel pharmacological therapies for myocardial remodelling. - Wikidata - awgldk - TriplyDB

Potential novel pharmacological therapies for myocardial remodelling.

Potential novel pharmacological therapies for myocardial remodelling.

http://www.wikidata.org/entity/Q37329709

about

Role of microRNAs in the reperfused myocardium towards post-infarct remodelling What can we learn about treating heart failure from the heart's response to acute exercise? Focus on the coronary microcirculation Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.Proteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction.Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.Beneficial effects of SR33805 in failing myocardium.Remodeling after acute myocardial infarction: mapping ventricular dilatation using three dimensional CMR image registration.Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significance Co-treatment with conjugated linoleic acid and nitrite protects against myocardial infarction.Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function.Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation.Innate immune signaling in cardiac ischemia.Novel therapeutic targets for the treatment of heart failure.Impact of diabetes on postinfarction heart failure and left ventricular remodeling.Fibrosis and heart failure.The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II.Antagonist molecules in the treatment of angina Transforming Growth Factor-β Receptor III is a Potential Regulator of Ischemia-Induced Cardiomyocyte Apoptosis.Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction.Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor Postmyocardial infarct remodeling and heart failure: potential contributions from pro- and antiaging factors.Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction.Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial.SOD1 overexpression in paraventricular nucleus improves post-infarct myocardial remodeling and ventricular function.Analysis of microRNA Expression Profiles Induced by Yiqifumai Injection in Rats with Chronic Heart Failure.Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.Biomaterials and heart recovery: cardiac repair, regeneration and healing in the MCS era: a state of the "heart"Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling

P2860

Q27000076-F2B9469E-E2FF-48A4-80FF-7703FE1CC81F Q28083350-ED8B6B0B-CAD0-4F7E-B9A0-4B6E7DCB865A Q33902466-3A5DC7FC-68CE-406D-8061-0D6A5FA893C4 Q34126907-81D91F1F-798A-4453-BB3B-748752B2270B Q34427625-55217408-1F9A-42BA-BD3D-0804C00C02A5 Q35114766-72092126-DD35-4068-8484-8AA39C52A678 Q36138836-4407FC2C-7701-49D2-83AF-A7F32890FF7A Q36529020-294DEBE6-29B9-4150-950B-908FD6D8FF3F Q37392069-BF83908A-A83A-4957-A28E-C706F8FF141C Q37728441-54188A89-7B41-4B31-BE62-973FD33F3674 Q37801768-04DEC284-D40E-4A55-9E76-BDF305FEBD44 Q37859249-A0145571-0141-4DA1-A303-EC027637A63A Q37893956-08E4A324-1889-4CA3-B89A-44E85D26758B Q37917623-9854B23C-DA23-4662-9484-E05B04E707AB Q38057701-F3AA8D17-5EC8-4A3D-B691-7B3541084D86 Q38110697-3FCBD8BE-01A6-4C5C-8F22-60072987BA4D Q38139089-6A9F7FD8-D91B-460B-B5BF-E430AE4EAC29 Q40179995-089C2762-9FAE-4222-B8D2-055DA6FB4271 Q40435871-239B3CF6-B353-480F-96B3-6DBB203E39A7 Q41538962-D9700785-FDDB-4954-AC1D-48239131E6A3 Q42011791-B1FA9507-3DE7-4DCB-82D6-681C7CDD0B6A Q42033846-A70BDB3C-9E8D-4D62-B047-9A4F9DFAB86D Q43282310-634C5EFD-C5FD-44D4-BB61-1978E2097A32 Q43502186-208D4FB7-6D4B-4E17-9708-D418FDF38BFD Q48832185-83470E74-E3B4-42F6-A589-0096F8EAEA27 Q50296013-E68FE423-D629-4720-BF6F-4369724C47C0 Q52886208-E9308D53-596A-42B9-9FCD-8651678125FC Q56376510-DD8D86CC-C4C2-41B3-B6BA-ABE501BBE2CB Q57312498-85144C2A-5D9F-478F-8BC5-C265C52414F8

P2860

Potential novel pharmacological therapies for myocardial remodelling.

http://www.wikidata.org/entity/Q37329709

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Potential novel pharmacological therapies for myocardial remodelling.

@en

Potential novel pharmacological therapies for myocardial remodelling.

@nl

type

label

Potential novel pharmacological therapies for myocardial remodelling.

@en

Potential novel pharmacological therapies for myocardial remodelling.

@nl

prefLabel

Potential novel pharmacological therapies for myocardial remodelling.

@en

Potential novel pharmacological therapies for myocardial remodelling.

@nl

P1433

Q37329709-D3839E3C-4045-4645-AB7C-ECEC119F3EBB

P1476

Q37329709-884A6246-2D48-4EEA-8376-DF85F7E853A4

P2093

Q37329709-BA75BEF7-5205-4D4D-90B4-0082491F30B5

Q37329709-EF726D92-ECB0-493F-9BF9-663EFEDD7469

P2860

Q37329709-03983286-7393-40D7-9527-49DD37788476

Q37329709-0D6F3650-F1DF-440A-ABF6-37D12DC5F7C9

Q37329709-10554CBC-D149-4418-B748-F280E34FDA67

Q37329709-166BB7BC-D389-4AA2-9A2F-DCA1D9D74399

Q37329709-16C072E9-FC0B-43D5-8159-B7370AB0D918

Q37329709-1C82AEC7-4C22-4131-833D-CE52C0BF26BB

Q37329709-21F09384-0B96-4A9C-9E1C-B16C24572933

Q37329709-22DEAC44-4614-4820-A1EB-EF740480A397

Q37329709-23E39E53-5EC7-4451-8D93-C718E214F815

Q37329709-26BD83C6-C04E-4997-99AB-A021D9910D29

P304

Q37329709-ECF64B14-FEC1-46C9-9B9E-FB13A65B584E

P31

Q37329709-3FABE2A3-06A4-48E8-9B24-4CE5D5C14A6D

P356

Q37329709-5B185BBD-C9DF-4601-ADB7-0C21D038AB90

P433

Q37329709-EC8E8B0A-56A1-4008-B837-915F724AEA1A

P478

Q37329709-23AD4B30-2EE2-4FB6-B9AF-CF03D9D54995

P50

Q37329709-7643CF38-F03E-4BF7-B8AA-AD0B402B408E

P577

Q37329709-49E6FA35-5B28-407D-90F9-0CD8E00903B8

P5875

Q37329709-4DA8F3A3-3F97-4C2B-BCDB-86C12CEF37EE

P698

Q37329709-9781F1C2-4127-4102-99EC-9325F785DB17

P921

Q37329709-1FC8E519-A415-4A47-81B4-22BFD0AA4FCB

P356

P1433

Cardiovascular Research

P1476

Potential novel pharmacological therapies for myocardial remodelling.

@en

P2093

Helmut Drexler

http://www.w3.org/2001/XMLSchema#string

Kai C Wollert

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart

cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes

Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair

Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice.

Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.

The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.

Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction.

P304

519-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVN317

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23483914

http://www.w3.org/2001/XMLSchema#string

P698

19019834

http://www.w3.org/2001/XMLSchema#string

P921